Arrow International v. Spire Biomedical, Inc.

443 F. Supp. 2d 182, 2006 U.S. Dist. LEXIS 58160
CourtDistrict Court, D. Massachusetts
DecidedAugust 15, 2006
DocketCivil Action 05-10671-DPW
StatusPublished
Cited by2 cases

This text of 443 F. Supp. 2d 182 (Arrow International v. Spire Biomedical, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Arrow International v. Spire Biomedical, Inc., 443 F. Supp. 2d 182, 2006 U.S. Dist. LEXIS 58160 (D. Mass. 2006).

Opinion

MEMORANDUM

WOODLOCK, District Judge.

Arrow International Investment Corp. is the owner of United States Patent No. 6,872,198 ('198), entitled “Double-Y-Shaped Multi-Lumen Catheter with Selectively Attachable Hubs.” Arrow International, Inc. is the exclusive licensee of this patent. Plaintiffs (collectively “Arrow”) brought this suit alleging that Defendant Spire Biomedical, Inc.’s (“Spire”) manufacture and sale of the Pourchez RetrO high flow kink resistant catheter infringes the '198 patent. Spire counterclaimed for a declaratory judgment of non-infringement, invalidity, and unenforceability contending, inter alia, that the '198 now lies in an abandoned state.

While this case was pending, Arrow initiated a proceeding before the Patent and Trademark Office to resolve the question of abandonment. I find that Arrow must exhaust its administrative remedies before the PTO regarding abandonment as a condition precedent to pursuit of this patent litigation by either party in an Article III court. As a consequence, I have dismissed this action without prejudice to reinitiated judicial proceedings following PTO administrative determination regarding abandonment of the '198 patent.

I.

Spire alleges that the '198 patent is invalid because it was abandoned by operation of law pursuant to 35 U.S.C. § 122(b). Under § 122(b)(2)(A)(iii) the failure to provide proper notice to the PTO that application has been made to another jurisdiction for patent protection results in the American patent being “regarded as being abandoned.” ■ •

Section 122(b)(1)(A) requires that applications to the PTO for patents be published eighteen months after the filing date. Section 122(b)(2)(B)(i) provides an exception to this automatic publication provision:

If an applicant makes a request upon filing, certifying that the invention disclosed in the application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing, the application shall not be published as provided in paragraph (1).

*184 The statute also allows an applicant to “rescind a request made under clause (i) at any time.” § 122(b)(2)(B)(ii).

For applicants who make non-publication requests pursuant to § 122(b)(2)(B)®, but who subsequently file in a foreign country or under a multilateral international agreement, there are timeliness requirements for a rescission request. Those applicants must “notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application.” § 122(b)(2)(B)(iii). Failure to provide that notice, “shall result in the application being regarded as abandoned.” Id. An application abandoned in this manner may be revived only by filing a formal petition for revival with the PTO stating that the delay was unintentional. 35 U.S.C. § 122(b)(2) (B) (iii).

II.

The application for the '198 patent was filed in the PTO on August 30, 2002, and assigned application number 10/231,748. At the time the application was filed, the inventors, who worked for Diatek, a company focused on developing catheters for use with a retrograde insertion technique, filed a nonpublication request, which stated:

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

Arrow acquired Diatek’s assets, including the application for the '198 patent, sometime in 2003. On August 28, 2003, Arrow submitted to the PTO an international application under the Patent Cooperation Treaty (PCT) for the '198 patent, no. 10/231,748. The PCT application included a request by Arrow that the PTO provide a certified copy of the U.S. application to the International Bureau.

Based on Arrow’s PCT filing, the application for the '198 patent was published by the PTO on March 11, 2004 as International Publication No. WO 2004/0020019. Arrow also applied separately for patents in Canada, Japan, Mexico, China, Australia, and the European Patent Office between February 28 and March 25, 2005.

Arrow filed the instant infringement action on April 5, 2005. About a year later, on March 22, 2006, Spire filed a motion for summary judgment based on abandonment under § 122(b)(2)(B)(iii). The next day, on March 23, 2006, Arrow submitted a request for rescission of its prior nonpublication request together with a Petition for Revival of Potentially Abandoned Application Pursuant to 37 C.F.R. § 1.137(b). Arrow claims that the possibility of abandonment was first brought to its attention on March 22, 2006, when Spire filed its motion for summary judgment and Markman determinations. Arrow sought a stay of its response obligations and of the previously scheduled Markman /summary judgment hearing, arguing that the doctrine of primary jurisdiction counseled awaiting the outcome of the PTO revival process before proceedings in this court should move forward. In order to understand the issues more fully in context, I denied the motion to stay. With briefing completed, I held the scheduled hearing on all issues and, following the hearing, permitted additional briefing on the question of the impact of the revival proceeding. Having considered the matter in full context, I determined to dismiss this case without prejudice on grounds of failure to exhaust administrative remedies as to the abandon *185 ment question. This Memorandum explains my reasons for doing so.

III.

On the merits of abandonment, the parties argued before me the questions (a) whether Arrow’s filing of the PCT constitutes adequate notice for purposes of § 122 (b) (2) (B) (iii), and if not, (b) whether the rescission and petition for revival that it filed in March 2006 preclude a finding of abandonment.

There is, however, a threshold step that must be undertaken before the parties may come into an Article III court for answers to these questions. That threshold is completion of the PTO revival process. If Arrow is successful before the PTO, Spire may challenge the revival and argue its implications before a District Court in a subsequently refiled patent litigation. Suntiger, Inc. v. Telebrands Advertising, Inc., 1997 WL 855581 (E.D.Va. July 11, 1997). If Arrow is unsuccessful before the PTO, Arrow must litigate the questions of revival successfully through the Federal Circuit, 35 U.S.C. § 141, or perhaps alternatively in the United States District Court for the District of Columbia, 35 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
443 F. Supp. 2d 182, 2006 U.S. Dist. LEXIS 58160, Counsel Stack Legal Research, https://law.counselstack.com/opinion/arrow-international-v-spire-biomedical-inc-mad-2006.